Oxytocin and Tibolone
Phase 1Small molecule
Oxytocin and Tibolone is one of 54 small molecule programs targeting Treatment Resistant Depression. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
62 competitors in Treatment Resistant Depression
#DrugCompanyPhaseTrials
1Ketalar
AAultman Health Foundation
Approved
Spravato
WWim Janssens
Approved
Bayer Aspirin
BayerApproved
Lithobid
SSolvay Pharmaceuticals
Approved
Abilify
OtsukaApproved
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Mirapex
Boehringer IngelheimApproved
Wellbutrin
GGlaxo Dba Glaxosmithkline
Approved
Gocovri
GGrupo Espanol de Tumores Neuroendocrinos
Approved
Lithobid
SSolvay Pharmaceuticals
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Oxytocin and Tibolone. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- TThe Alfred